Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Calidi Biotherapeutics ( (CLDI) ) is now available.
On January 28, 2026, Calidi Biotherapeutics recapped its 2025 progress and outlined operational priorities for 2026, highlighting preclinical data presented in May and November 2025 that showed its RedTail platform and lead asset CLD-401 can avoid immune clearance after systemic administration, selectively replicate in tumor cells at metastatic sites, and deliver IL-15 superagonist locally at levels comparable to localized dosing. During 2025, the company strengthened its leadership with a new CEO, Eric Poma, and CMO, Guy Travis Clifton, reconstituted its scientific advisory board with high-profile oncology and drug development experts, and improved its balance sheet by cutting term debt and notes payable from $3.8 million to $0.7 million and reducing general and administrative expenses over the first nine months of the year, moves that collectively aim to support the advancement of CLD-401 and broader RedTail platform applications in oncology and potential non-oncology indications.
The most recent analyst rating on (CLDI) stock is a Hold with a $0.97 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Neutral.
The score is held down primarily by continued lack of revenue, sizable losses, and heavy cash burn, which create ongoing financing/dilution risk. Technicals add further pressure with a clear downtrend and weak momentum. Offsetting factors include improved leverage/positive equity and constructive corporate updates (financing and development progress), but they are not enough to outweigh the core financial and trend risks.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Calidi Biotherapeutics, Inc., headquartered in San Diego and listed on the NYSE American, operates in the biotechnology industry, focusing on systemically delivered, targeted genetic medicines for metastatic disease. Its proprietary RedTail platform uses an engineered enveloped oncolytic virus designed to evade immune clearance, home to metastatic tumor sites, induce tumor lysis, and deliver high local concentrations of genetic payloads, with lead candidate CLD-401 currently in IND-enabling studies for non-small cell lung cancer, head and neck cancer and other solid tumors with high unmet need.
Average Trading Volume: 127,980
Technical Sentiment Signal: Sell
Current Market Cap: $7.17M
For a thorough assessment of CLDI stock, go to TipRanks’ Stock Analysis page.